XML 22 R10.htm IDEA: XBRL DOCUMENT
v3.25.3

Supplemental Financial Information | 9 Months Ended
--- | ---
Sep. 30, 2025
Supplemental Financial Information [Abstract] |
Supplemental Financial Information | Supplemental Financial Information Tempus agreement In November 2023, Recursion entered into a five-year agreement (the Tempus Agreement) with Tempus AI, Inc. (“Tempus”) t o purchase access to their records of patient-centric multimodal oncology data and use rights for therapeutic development purposes. This data will be used to improve the training of Recursion’s artificial intelligence and machine learning models and is expected to accelerate Recursion’s drug discovery process. Recursion is making annual payments, ranging between $22.0 million and $42.0 million, up to $160.0 million in aggregate, to Tempus in cash or equity at the Company’s option. The equity value is determined by using the seven-trading day period dollar volume-weighted average price (VWAP) for Recursion Class A common stock ending on the day immediately preceding the date that is five business days prior to the payment date. Recursion is expensing the record purchases based on a contractually agreed price as “Research and Development” expenses in the Condensed Consolidated Statements of Operations as the records are downloaded. To the extent that the Recursion payments to Tempus are greater than or less than the records purchased amount, Recursion records the applicable amount to “Prepaid data assets” or “Accrued data liability” on the Condensed Consolidated Balance Sheet, respectively. The expense for the record purchases was $49.9 million and $2.9 million for the nine months ended September 30, 2025 and 2024. There was no expense recorded for the three months ended September 30, 2025 and 2024. Accrued Expenses and Other Liabilities
| September 30, | December 31,
(in thousands) | 2025 | 2024
Accrued compensation | $ | 24,056 |  | $ | 50,853 |
Accrued development expenses | 2,497 |  | 5,812 |
Accrued early discovery expenses | 7,840 |  | 3,095 |
Accrued professional fees | 1,956 |  | 787 |
Materials received not invoiced | 1,206 |  | 1,590 |
Accrued license fees | 3,000 |  | 3,000 |
Accrued other expenses | 12,547 |  | 16,735 |
Accrued expense and other liabilities | $ | 53,102 |  | $ | 81,872 |
Restructuring In June 2025, Recursion announced a reduction in personnel program to help streamline the Company's operating strategy and post-integration efficiencies. These changes resulted in a workforce reduction of approximately 20%. The Company estimates that it will incur approximately $9.5 million in charges for the workforce reduction, consisting of severance payments and employee benefits. Recursion expects to incur all of these expenses in the year ending December 31, 2025. Recursion records these costs in “General and Administrative” on the Condensed Consolidated Statement of Operations as incurred. The following summarizes the activity related to these restructuring actions and the related accrual as of September 30, 2025:
(in thousands) |
Balance as of December 31, 2024 | $ | — |
Expense | 8,516 |
Payments | (7,717) |
Balance as of September 30, 2025 | $ | 799 |
Interest Income, Net
| Three months ended September 30, |  | Nine months ended September 30,
(in thousands) | 2025 | 2024 |  | 2025 | 2024
Interest income | $ | 5,540 |  | $ | 3,826 |  |  | $ | 16,541 |  | $ | 11,138 |
Interest expense | (833) |  | (553) |  |  | (1,821) |  | (967) |
Interest income, net | $ | 4,707 |  | $ | 3,273 |  |  | $ | 14,720 |  | $ | 10,171 |
For the three and nine months ended September 30, 2025 and 2024, interest income primarily related to earnings on cash and cash equivalents in money market funds. Interest expense primarily related to the Company’s supercomputer financing lease. Interest income, net was included in “Other income (loss), net” on the Condensed Consolidated Statements of Operations.

X
- Definition Supplemental Balance Sheet And Income Statement Information + References No definition available. + Details
Name: | rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock
Namespace Prefix: | rxrx_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Supplemental Financial Information + References No definition available. + Details
Name: | rxrx_SupplementalFinancialInformationAbstract
Namespace Prefix: | rxrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration